Carvacrol reduces blood pressure, arterial responsiveness and increases expression of MAS receptors in spontaneously hypertensive rats

Imagem de Miniatura
Arquivos
art_DIAS_Carvacrol_reduces_blood_pressure_arterial_responsiveness_and_increases_2022.PDF (2.11 MB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
DIAS, Carlos Jose
COSTA, Herikson Araujo
DIAS-FILHO, Carlos Alberto Alves
FERREIRA, Andressa Coelho
RODRIGUES, Bruno
BORGES, Antonio Carlos Romao
MARTINS, Vicenilma de Andadre
VIDAL, Flavia Castello Branco
RIBEIRO, Rachel Melo
Citação
EUROPEAN JOURNAL OF PHARMACOLOGY, v.917, article ID 174717, 7p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aim: To analyze the effect of the use of carvacrol in the cardiovascular system of spontaneously hypertensive rats (SHR). Methods: Methods: Twenty animals were allocated in four groups, one group control Wistar receiving only sorbitol, used as vehicle of administration of the carvacrol (Wistar-Vehicle), one control group SHR, also receive only sorbitol (SHR-Vehicle), a third, treated with losartan (SHR-Losartan/50 mg/kg), and the fourth, treated with carvacrol (SHR - Carvacrol/20 mg/kg). Sorbitol, losartan and carvacrol were administered by oral gavage daily for 30-day. Hemodynamic variables, vascular reactivity, biochemical parameters, and expression of Mas and AT1 receptors in kidney tissues were analyzed. Results: SHR- Carvacrol group showed a maximal effect of inhibition of 56% in the curve of norepinephrine. The Emax of the curves with Ca2+ were smaller in the groups SHR-losartan (40.17%) and SHR-carvacrol (35.71%) when compared to the SHR-Vehicle. The carvacrol increased the expression of the MAS receptors in kidney tissue. Conclusion: Thirty days of treatment with carvacrol showed an antihypertensive effect associated with less peripheral vascular resistance. Also, treatment with carvacrol increased the expression of MAS receptors in kidney tissue.
Palavras-chave
Carvacrol, Cardiovascular, Hypertension
URI
https://observatorio.fm.usp.br/handle/OPI/55040
Referências
  1. Adaramoye OA, 2009, J ETHNOPHARMACOL, V124, P457, DOI 10.1016/j.jep.2009.05.021
  2. Alexander LM, 2006, DRUGS, V66, P1239, DOI 10.2165/00003495-200666090-00006
  3. Anjos PJC, 2013, Z NATURFORSCH C, V68, P181
  4. Arunasree KM, 2010, PHYTOMEDICINE, V17, P581, DOI 10.1016/j.phymed.2009.12.008
  5. Aydin Y, 2007, PLANTA MED, V73, P1365, DOI 10.1055/s-2007-990236
  6. Bakkali F, 2008, FOOD CHEM TOXICOL, V46, P446, DOI 10.1016/j.fct.2007.09.106
  7. Matos VSB, 2017, J BRAS PNEUMOL, V43, P208, DOI [10.1590/S1806-37562016000000144, 10.1590/s1806-37562016000000144]
  8. Bastos JFA, 2010, BASIC CLIN PHARMACOL, V106, P331, DOI 10.1111/j.1742-7843.2009.00492.x
  9. Calixto JB, 2000, BRAZ J MED BIOL RES, V33, P179, DOI 10.1590/S0100-879X2000000200004
  10. Melo FHC, 2010, FUND CLIN PHARMACOL, V24, P437, DOI 10.1111/j.1472-8206.2009.00788.x
  11. Costa HA, 2021, EXP PHYSIOL, V106, P891, DOI 10.1113/EP089235
  12. Daferera DJ, 2000, J AGR FOOD CHEM, V48, P2576, DOI 10.1021/jf990835x
  13. Docherty JR, 2010, CELL MOL LIFE SCI, V67, P405, DOI 10.1007/s00018-009-0174-4
  14. Durmowicz A G, 1999, Pediatr Rev, V20, pe91
  15. El-Sayed EM, 2016, J BIOCHEM MOL TOXIC, V30, P37, DOI 10.1002/jbt.21740
  16. Ferrario CM, 2011, CURR OPIN NEPHROL HY, V20, P1, DOI 10.1097/MNH.0b013e3283406f57
  17. Ferreira AJ, 2010, HYPERTENSION, V55, P207, DOI 10.1161/HYPERTENSIONAHA.109.140145
  18. Gao L., 2017, HYPERTENS HYPERTENSI, V117
  19. GREENBERG S, 1982, ARCH INT PHARMACOD T, V258, P208
  20. GURNEY AM, 1994, J PHARM PHARMACOL, V46, P242, DOI 10.1111/j.2042-7158.1994.tb03789.x
  21. Kashihara T, 2017, J PHYSIOL-LONDON, V595, P4207, DOI 10.1113/JP273883
  22. Kawai T, 2017, PHARMACOL RES, V125, P4, DOI 10.1016/j.phrs.2017.05.008
  23. Kjeldsen SE, 2018, PHARMACOL RES, V129, P95, DOI 10.1016/j.phrs.2017.11.003
  24. Kuczeriszka M, 2018, AM J HYPERTENS, V31, P504, DOI 10.1093/ajh/hpy006
  25. Llana-Ruiz-Cabello M., 2016, FOOD CHEM TOXICOL, V98
  26. Marin J, 1998, LIFE SCI, V64, P279, DOI 10.1016/S0024-3205(98)00393-2
  27. NELSON MT, 1990, AM J PHYSIOL, V259, pC3
  28. Nicolau JC, 2014, ARQ BRAS CARDIOL, V103, P183, DOI [10.5935/abc.20140106, 10.5935/abc.2014S001]
  29. Passos-Silva DG, 2013, CLIN SCI, V124, P443, DOI 10.1042/CS20120461
  30. Patten GS, 2016, CRIT REV FOOD SCI, V56, P181, DOI 10.1080/10408398.2011.651176
  31. Peixoto-Neves D, 2010, FUND CLIN PHARMACOL, V24, P341, DOI 10.1111/j.1472-8206.2009.00768.x
  32. Perez-Vizcaino F, 1998, BRIT J PHARMACOL, V123, P847, DOI 10.1038/sj.bjp.0701693
  33. Pessoa BS, 2013, NAT REV NEPHROL, V9, P26, DOI 10.1038/nrneph.2012.249
  34. Piascik MT, 1996, PHARMACOL THERAPEUT, V72, P215, DOI 10.1016/S0163-7258(96)00117-9
  35. Rajput J.D., 2017, MOL DIVERS, P1
  36. Sampaio WO, 2007, HYPERTENSION, V49, P185, DOI 10.1161/01.HYP.0000251865.35728.2f
  37. Santos MRV, 2011, REV BRAS FARMACOGN, V21, P764, DOI 10.1590/S0102-695X2011005000119
  38. Suzuki R, 2014, AM J HYPERTENS, V27, P695, DOI 10.1093/ajh/hpt208
  39. Zhang F, 2019, NITRIC OXIDE-BIOL CH, V88, P1, DOI 10.1016/j.niox.2019.03.007

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/59
Artigos e Materiais de Revistas Científicas - LIM/65